Vedantra Pharmaceuticals

BiotechnologySeries BCambridge, USvedantra.com

Latest round

Series B

Last raised

Nov 2018

Total raised

$3.3M

Investors

2

About Vedantra Pharmaceuticals

Founded in 2011 and based in Massachusetts, Vedantra Pharmaceuticals, Inc. is a company that develops vaccines for infectious diseases and cancer. The company uses nanotechnology-based approaches in the development of vaccines.

Who invested in Vedantra Pharmaceuticals

2 investors across 2 rounds

See all investors in Vedantra Pharmaceuticals

Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.

Funding rounds

  1. Series B

    Nov 6, 2018

    Amount

    Undisclosed

    Investors

    Locked

  2. Series A

    Aug 3, 2012

    Amount

    $3.3M

    Investors

    Locked

Questions about Vedantra Pharmaceuticals

Who invested in Vedantra Pharmaceuticals?

Vedantra Pharmaceuticals has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.

How much funding has Vedantra Pharmaceuticals raised?

Vedantra Pharmaceuticals has raised 2 venture rounds. Sign up free to see how much each round raised and the total.

When did Vedantra Pharmaceuticals last raise money?

Vedantra Pharmaceuticals's most recent round on record is a Series B, in Nov 2018.

What does Vedantra Pharmaceuticals do?

Founded in 2011 and based in Massachusetts, Vedantra Pharmaceuticals, Inc.

Where is Vedantra Pharmaceuticals headquartered?

Vedantra Pharmaceuticals is headquartered in Cambridge, US.

Which VCs invest in companies like Vedantra Pharmaceuticals?

Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Vedantra Pharmaceuticals's stage. Their profiles are linked below.

Raising like Vedantra Pharmaceuticals? Find the right VCs.

Capital Atlas matches your startup to active investors by stage, sector and region.

Free to start. Upgrade when you're ready to reach out.